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o We Need Yet
nother Blocker of the
enin-Angiotensin System?*
ranz H. Messerli, MD, FACC,†
ichard N. Re, MD‡
ew York, New York; and New Orleans, Louisiana
s of the latest count in the U.S., there are 10 angiotensin-
onverting enzyme (ACE) inhibitors and 7 angiotensin
eceptor blockers (ARBs) in the therapeutic arsenal. Al-
hough in meta-analyses some outcome differences were
ocumented between ACE inhibitors as a class and ARBs
s a class, the main differences within both classes seem to
e mostly related to pharmacokinetics, perhaps with the
xception of the antihypertensive efficacy that has been
hown to vary from one ARB to another by a very few
illimeters of mercury (1). To merit the label “better,” a
ew drug has to be either more efficacious or safer (or both)
han existing drugs. In hypertensive cardiovascular disease,
See page 1157
ore efficacious means a better reduction of heart attacks,
trokes, and end-stage renal disease, and safer means fewer
dverse effects than ARBs or ACE inhibitors. Some but not
ll ACE inhibitors and ARBs have been shown to confer
rotection of the heart, the kidneys, and the brain. As a
lass, ACE inhibitors seem to be somewhat more effective
han ARBs for cardioprotection, whereas the reverse may be
rue for cerebroprotection. However, whether and to what
xtent such protection is independent of the fall in blood
ressure remains the subject of an ongoing debate.
With regard to safety, most clinicians have the impression
hat both classes are well tolerated, the only adverse effect
eing cough (common) and angioedema (rare) with the
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erck.CE inhibitors. There seems little doubt that the new class
i.e., renin inhibitors [2]) will beat the ACE inhibitor in
erms of side effects. However, to outdo the ARBs either in
erms of efficacy or safety will be a formidable challenge.
ne may therefore appropriately ask whether the introduc-
ion of yet another class of renin-angiotensin-aldosterone
ystem (RAAS) blockers will fulfill a clinical need or merely
dd to the bottom line of the product manufacturer.
A comparison of the biochemical features clearly shows
hat there are differences among the 3 drug classes (Table 1).
he question is whether any of these differences will
ltimately translate in clinically meaningful differences in
utcome. In other words, for the same decrease in blood
ressure, will renin inhibitors confer more organ protection
han do ARBs or ACE inhibitors, i.e., is the patient at a
esser risk of heart attack, congestive heart failure, stroke or
enal failure? This question has not been conclusively
nswered in a head-to-head comparison between an ACE
nhibitor and an ARB. It therefore seems unlikely that a
harmaceutical company would be courageous enough to
ount a large outcome trial comparing a renin inhibitor
ith either an ARB or an ACE inhibitor. The most likely
cenario is that practicing physicians will periodically be
poon-fed small potboiler studies showing some improve-
ent of surrogate end points (such as left ventricular mass
r albuminuria) with renin inhibitors.
The study by Oh et al. (3) in this issue of the Journal
hows that the antihypertensive efficacy of aliskiren is very
imilar to what we have seen with ACE inhibitors and
RBs. A 4-fold escalation of the dose (from 150 to 600 mg)
erely yielded a 2.5 or 2.2 mm Hg additional fall in blood
ressure. When placebo was subtracted from the blood
ressure fall with the 2 well-tolerated aliskiren doses (150
nd 300 mg) a single-digit decrease in systolic and diastolic
ressure was observed. Thus, similar to ACE inhibitors and
RBs, the dose response of blood pressure with aliskiren
eems to be shallow and to plateau at or even below the
DA-approved maximal dose.
However, renin inhibitors could also be attractive if they
ere shown to have fewer adverse effects but similar organ
rotection and outcome as ACE inhibitors and ARBs. We
hould remember that angioedema is a rare but potentially
atal adverse effect of ACE inhibitors. Given that millions
f patients are exposed to these drugs, a substantial number
f drug-associated fatalities can be estimated to occur every
ear (4). In contrast, ARBs are exceedingly well tolerated
nd have often been shown to have even fewer adverse
ffects than placebo. The fact that ARBs are well tolerated
llows us to test the hypothesis that some features of target
rgan protection may not be related to the fall in blood
ressure. The hypothesis of enhanced organ protection with
igher than FDA-approved doses is currently explored by 3
ifferent studies with 640 mg valsartan, 128 mg candes-
rtan, and 900 mg irbesartan. Should this concept bear fruit
nd indeed enhanced target organ protection be conferred
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March 20, 2007:1164–5 Editorial Commenty high ARB doses, then the question of combination
herapy efficacy and safety would have to be reassessed. Will
he addition of a renin inhibitor to high-dose ARB and/or
CE inhibitor therapy further enhance target organ pro-
ection, and, most importantly, will susceptible patients (i.e.,
hose with diabetes and chronic renal failure) tolerate such
ombinations? That said, it is now clear that (pro)renin
eceptors of various sorts exist and that binding of prorenin
o at least one of these receptors is associated both with
ncreased angiotensin II generation at the target cell surface
nd with direct stimulation of intracellular second messen-
er signaling pathways (5). Indeed, Luetscher et al. (6),
ore than 20 years ago, related prorenin levels to micro-
ascular complications in diabetic patients. In diabetic
nimal models, prorenin binding to this receptor has been
hown to exert angiotensin-independent, unlike ACE in-
ibitors or ARBs, pathologic effects in target tissues such as
he kidney (5). If renin inhibitors, unlike ACE inhibitors or
RBs, effectively block either the enhanced generation of
ngiotensin II at the cell surface receptor or alter the ability
f prorenin to directly signal at the receptor, a new mech-
nism for the inhibition of the cardiovascular complications
f diabetes—a condition associated with high circulating
rorenin concentrations—and hypertension could be at
ndocrine Differences Amongenin-A giotensi -Aldosterone System Blockers
Table 1 Endocrine Differences AmongRenin-Angiotensin-Aldosterone System Blockers
ACE
Inhibitors ARBs
Renin
Inhibitors
Enzymes
Plasma renin activity Increased Increased Inhibited
Plasma renin concentration Increased Increased Increased
Plasma ACE/tissue ACE Inhibited Not inhibited Not inhibited
Substrate concentrations
Angiotensinogen Decreased Decreased No change
Ang I Increased Increased Decreased
Bradykinin Increased No change No change
End products
Ang II Decreased Increased Decreased
Non–ACE-dependent Ang II Present Blocked Blocked
Ang III, Ang IV Decreased Increased Decreased
Ang(1–7) Increased Increased Decreased
Aldosterone Decreased Decreased Decreased
CE  angiotensin-converting enzyme; Ang  angiotensin; ARB  angiotensin receptor blocker.and. It will be interesting to see how this plays out (5).
8With regard to adverse effects of renin inhibitors, the
eport of Oh et al. (3) is not entirely reassuring. Diarrhea
as a dose-dependent adverse effect and occurred in more
han 10% of patients with the 640 mg dose. Gastrointestinal
dverse effects with any RAAS blocker invariably raise the
ssue of intestinal angioedema which has been reported with
CE inhibitors (4,7). We also should consider that long-
erm adverse effects have been poorly documented with all
ntihypertensive drug classes with the exception perhaps of
he diuretics and beta-blockers. The fact that these drugs
re “safe” when taken for a few months or a year does not
llow us to extrapolate that they will be safe when taken
or years and decades which is common for antihyper-
ensive therapy (8).
Modern antihypertensive therapy has spoiled patients and
hysicians. Blood pressure can now be lowered with comfort
nd convenience in most patients. Although the arrival of a
ew drug class such as the renin inhibitors is exciting and
hould be welcomed, its exact place in the antihypertensive
rsenal will depend on extensive documentation of efficacy
nd safety.
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oosevelt Hospital Center, 1000 Tenth Avenue, New York,
ew York 10019. E-mail: fmesserli@aol.com.
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